Targets › GABRA1
57 programs from 48 companies in 97 trials: 45 Phase 4, 20 Phase 3, 18 Phase 2, 14 Phase 1; Other, Psychiatry, Neurology; next expected readout Nov 2026.
Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain. GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s). (UniProt, P14867)
Open in Phaseline: the race on GABRA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rush University Medical Center | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Minor Surgical Procedures With Monitored Anesthesia Care | Nov 2026 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Propofol GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Lung Cancer; Hepatocellular Carcinoma; Ovarian Cancer | Nov 2026 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Sevoflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 4 | Lung Cancer; Hepatocellular Carcinoma; Ovarian Cancer | Nov 2026 |
| University of Sao Paulo | Eszopiclone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Insomnia | Dec 2026 |
| University Hospitals Cleveland Medical Center | Valtoco Nasal Product Benzodiazepine (diazepam) nasal spray for acute seizure management | GABRA1 | Phase 4 | Epilepsy | Dec 2026 |
| VA Office of Research and Development | Zolpidem GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | GABRA1, GABRG2, GABRB1 | Phase 4 | Sleep Disordered Breathing | Dec 2026 |
| Medical University of South Carolina | Remimazolam besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Burn Scar | Jan 2027 |
| Rawalpindi Institute of Cardiology | Ketamine-Propofol NMDA receptor antagonist combined with GABA-A agonist | NMDAR, GABRA1 | Phase 4 | Propofol | Jan 2027 |
| Medical University of South Carolina | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Anesthesia Induction | Apr 2027 |
| Seoul National University Hospital | Remimazolam Besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Remimazolam; Aortic Aneurysm, Thoracoabdominal | Apr 2027 |
| SK Life Science | Cenobamate (YKP3089) GABA-A receptor; anion channel positive allosteric modulator; Sodium channel alpha subunit inhibitor | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Focal Onset Seizure; Partial Epilepsy | May 2027 |
| Clinical Hospital Centre Zagreb | Remimazolam besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Colonic Polyp | Nov 2027 |
| Medical University of Vienna | Desflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 4 | Postoperative Delirium | Dec 2027 |
| Laureate Institute for Brain Research, Inc. | Lorazepam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Depression, Anxiety | Dec 2027 |
| David Lyubashevsky | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Transcatheter Aortic Valve Replacement (TAVR) | Apr 2028 |
| University of Southern California | Zolpidem Tartrate GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | GABRA1, GABRG2, GABRB1 | Phase 4 | Spine Fusion | Jan 2029 |
| VA Office of Research and Development | Lorazepam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Stress Disorders, Post-Traumatic | Jun 2029 |
| Haisco Pharmaceutical Group | Cipepofol (HSK3486) GABA-A receptor; anion channel agonist | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Anesthesia; Myocardial Injury | – |
| Xi'an Aerospace General Hospital | Ciprofol GABA-A receptor positive allosteric modulator | GABRA1, GABRA2, GABRA3 | Phase 4 | Cholelithiasis | – |
| Georgia Tsaousi | Desflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 4 | Brain Edema Caused by Drugs | – |
| Hui Xu | Fospropofol disodium Intravenous general anesthetic prodrug | GABRA1 | Phase 4 | Drug Safety | – |
| University of Oklahoma | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Laceration of Skin | – |
| Universidade Federal de Goias | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Child Behavior | – |
| Beijing Shijitan Hospital, Capital Medical University | Remimazolam Besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Effect of Drug | – |
| Xi'an Aerospace General Hospital | Remimazolam besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Cholelithiasis | – |
| University of California, Los Angeles | CBD 20 mg GABA-A receptor; anion channel positive allosteric modulator | HTR1A, GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, SLC1A2, SLC1A3 | Phase 3 | Spinocerebellar Ataxias; Non-healing Wound; Sleep Apnea, Obstructive; Cervical Spinal Cord Injury … | Dec 2026 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Laceration of Skin | Dec 2026 |
| University of Texas Southwestern Medical Center | Propofol GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Anesthesia | Jan 2027 |
| Ono Pharmaceutical | Cenobamate GABA-A receptor; anion channel positive allosteric modulator; Sodium channel alpha subunit inhibitor | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Partial Epilepsy; Epilepsies, Partial | Jan 2027 |
| Ono Pharmaceutical | ONO-2017 Sodium channel modulator; GABA-A receptor positive allosteric modulator | Ion channels, GABRA1 | Phase 3 | Epilepsy, Generalized | Jan 2027 |
| Southeast University, China | Remimazolam besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Remimazolam Besylate | Jan 2027 |
| UCB Biopharma SRL | Alprazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Stereotypical Prolonged Seizures; Ophthalmology; Opioid Abuse; Drug Interactions | Mar 2027 |
| Emory University | Zolpidem GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | GABRA1, GABRG2, GABRB1 | Phase 3 | Orthopedic Trauma | Jul 2027 |
| Lipocine | Brexanolone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Depression, Postpartum; Alzheimer Dementia; PTSD | Aug 2027 |
| University Hospital, Montpellier | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Anesthesia | Oct 2027 |
| Xijing Hospital | desflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 3 | Cardiac Surgery | Dec 2028 |
| Yale University | Eszopiclone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Sleep Apnea | Jan 2030 |
| Sedana Medical | Isoflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 3 | Post-Intensive Care Syndrome; Diabete Mellitus; Sedation; Prevention of Delirium … | – |
| Stanford University | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Seizures | – |
| Romanian Society for Enteral and Parenteral Nutrition | Remimazolam Besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Postoperative Cognitive Dysfunction | – |
| Neurodawn Pharmaceutical | Y-4 combination of pregabalin (GABA analog) and riluzole (glutamate release inhibitor) | GABRA1, SLCX1 | Phase 2 | Postherpetic Neuralgia | Nov 2026 |
| Seaport Therapeutics | SPT-300 (GlyphAllo) Allopregnanolone prodrug; positive allosteric modulator of GABA-A receptors | GABRA1 | Phase 2 | Major Depressive Disorder (MDD) | Mar 2027 |
| University of California, Los Angeles | Intravenous Alcohol (6% ethanol v/v in saline) GABA-A receptor positive allosteric modulator; CNS depressant | GABRA1, GABRA2, GABRA3 | Phase 2 | Alcohol Use Disorder | Apr 2027 |
| Flinders University | Eszopiclone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | OSA - Obstructive Sleep Apnea | May 2027 |
| Duke University | Zuranolone Neuroactive steroid; GABA receptor positive allosteric modulator | GABRA1 | Phase 2 | Post Stroke Depression | Jun 2027 |
| Acacia Pharma | Remimazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Pediatric ALL; Benzodiazepines; Cataract Surgery; Sedation for Diagnostic Gastroscopy … | Oct 2027 |
| Stanford University | Zolpidem GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | GABRA1, GABRG2, GABRB1 | Phase 2 | Autism | Apr 2028 |
| University of California, Los Angeles | Eszopiclone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Obstructive Sleep Apnea | Aug 2028 |
| M.D. Anderson Cancer Center | Lorazepam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Delirium | Dec 2028 |
| Insel Gruppe AG, University Hospital Bern | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Anxiety | – |
| University Hospital, Grenoble | midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Neurocognitive Disorders | – |
| Yale University | Ethanol GABA-A receptor potentiator and NMDA receptor antagonist | GABRA1, GRIN1 | Phase 1 | Cannabis | Dec 2026 |
| CAMC Health System | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 1 | Anesthesia | Apr 2027 |
| Qianfoshan Hospital | Remimazolam Besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 1 | Chronic Kidney Diseases | Jun 2027 |
| Makassed General Hospital | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 1 | Healthy Female Volunteer | – |
| Beijing Tiantan Hospital | Y-4 tablet Fixed-dose combination of pregabalin (GABA analog/anticonvulsant) and riluzole (glutamate | GABRA1, SOD1 | Phase 1 | Healthy Male and Female Subjects | – |
| Umecrine Cognition | golexanolone Positive allosteric modulator of GABA-A receptor | GABRA1 | Phase 1 | Primary Biliary Cholangitis (PBC) | – |
Anesthesia (6) Cannabis (3) Partial Epilepsy (2) Healthy Male and Female Subjects (2) Lung Cancer (2) Hepatocellular Carcinoma (2) Ovarian Cancer (2) Cholelithiasis (2) Anxiety (2) Laceration of Skin (2) Major Depressive Disorder (MDD) (1) Epilepsies, Partial (1)
small molecule (56)
University of California, Los Angeles (3) Yale University (2) Ono Pharmaceutical (2) Kaohsiung Medical University Chung-Ho Memorial Hospital (2) Stanford University (2) Xi'an Aerospace General Hospital (2) VA Office of Research and Development (2) Medical University of South Carolina (2) Seaport Therapeutics (1) University Hospital, Grenoble (1) Southeast University, China (1) Duke University (1) Seoul National University Hospital (1) Lipocine (1) Beijing Tiantan Hospital (1) University Hospitals Cleveland Medical Center (1) Insel Gruppe AG, University Hospital Bern (1) Rawalpindi Institute of Cardiology (1) David Lyubashevsky (1) UCB Biopharma SRL (1)
GABRG2 (45) GABRB2 (41) GABRB3 (36) GABRA4 (36) GLRA1 (5) GLRB (5) GABRB1 (4) GABRA2 (2) GABRA3 (2) GRIN1 (1) SOD1 (1) HTR1A (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.